华人健康：关于全资子公司收到药品注册受理通知书的公告

Group 1 - The core point of the article is that Huaren Health announced the receipt of a drug registration application acceptance notice from the National Medical Products Administration for Dapagliflozin tablets [2] Group 2 - The announcement was made on the evening of October 23, indicating a significant regulatory milestone for the company [2] - The drug is developed by Jiangsu Shenhua Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huaren Health [2]